Company: ABBV
Filing Date: 2025-02-18
Form Type: 424B5
Source: 0001104659-25-014554
Chunk: 20

Company: AbbVie Inc.
Filing Date: 2025-02-18
Form: 424B5
Chunk 20
---
 substantially all of its assets through, its subsidiaries. AbbVie depends on distributions of cash flow and earnings from its subsidiaries in order to meet its payment obligations under the Notes and its other debt obligations. These subsidiaries are separate and distinct legal entities and will have no obligation to pay any amounts due on the Notes, or to provide AbbVie with funds for its payment obligations with respect thereto, whether by dividends, distributions, loans or otherwise. As a result, the Notes will be structurally subordinated to the liabilities of AbbVie’s subsidiaries, including trade payables. In addition, provisions of applicable law, such as those limiting the payment of dividends, could limit the ability of AbbVie’s subsidiaries to make payments or other distributions to it, and AbbVie’s subsidiaries could agree to contractual restrictions on their ability to pay dividends or make payments or other distributions to it. As of December 31, 2024, on a pro forma basis, giving effect to the issuance and sale of the Notes and the application of the estimated net proceeds therefrom (together with cash on hand), including the repurchase, redemption or repayment of the Issuer’s 3.600% senior notes due 2025, the Issuer’s 3.800% senior notes due 2025, and/or the 3.800% senior notes due 2025 of Allergan Funding SCS (formerly known as Actavis Funding SCS), as described in this prospectus supplement, and as if such transactions had occurred on December 31, 2024, AbbVie would have had approximately $ billion of outstanding indebtedness. In addition, AbbVie has unused borrowing capacity of up to $8.0 billion under the Revolving Credit Facilities.

#### Certain Covenants of AbbVie

#### Restrictions on Secured Debt
If AbbVie or any Domestic Subsidiary incurs, issues, assumes or guarantees any indebtedness for borrowed money represented by notes, bonds, debentures or other similar evidences of indebtedness for borrowed money (called “ Debt ”) and that Debt is secured by a Mortgage on any Principal Domestic Property, or any shares of stock or Debt of any Domestic Subsidiary, AbbVie will secure, or cause its Domestic Subsidiary to secure, the Notes equally and ratably with, or prior to, such secured Debt, so long as such secured Debt shall be so secured, unless, after giving effect thereto, the aggregate amount of all